Sensorion SA (ALSEN PA) stock market data APIs
€9.2585
0.13(1.4%)
as of November 5, 2026
Try our APIs with
free plan!
Sensorion SA Financial Data Overview
Price chart is built with
Anychart
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Prev. Close
9.2585
Open
9.3912
High
9.4451
Low
9.1989
52 wk Range
5.249-40.4
Market Cap
95 265 K
Shares Outstanding
10 307 K
Revenue
6 155 K
Beta
0.49
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sensorion SA data using free add-ons & libraries
Get Sensorion SA Fundamental Data
Sensorion SA Fundamental data includes:
- Net Revenue: 6 155 K
- EBITDA: -34 399 000
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-06-30
- EPS/Forecast: -0.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sensorion SA News
New
Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer
Dr. Weber, an otologist and neurotologist who led the clinical development of the first FDA-approved gene therapy for genetic hearing loss, joins as SENS-601 advances into the clinic MONTPELLIER, Fra...
Sensorion Announces the Completion of Its Reverse Share Split
Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5 Effective date of the reverse share split (listing of new shares): Septem...
Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report
GJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing;...
Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline
Sanofi’s investment marks the entry of a strategic shareholder Support from existing investors Redmile Group,Artal, which is advised by Invus, and Sofinnova Partners Participation from leading U.S. ...
Get Sensorion SA fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.